BioNotebook: Seragon, Arcturus, Seattle Genetics, Cytos, CIRM
This article was originally published in Scrip
Executive Summary
Seragon announces Series A funding amount; Arcturus raises $5m Series A; Seattle Genetics enters clinic with new ADC; Cytos earns Phase IIb cash; and CIRM president steps down.
You may also be interested in...
Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.